Jazz Pharmaceuticals’ Zanidatamab Study: A New Hope for Metastatic Breast Cancer?

Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.

Jazz Pharmaceuticals is conducting a Phase 3 study titled A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. The study aims to evaluate the effectiveness and safety of zanidatamab combined with chemotherapy compared to trastuzumab with chemotherapy in patients with metastatic HER2-positive breast cancer who have not responded to previous treatments. This study is significant as it explores new treatment options for a challenging cancer type.

The study tests two interventions: zanidatamab and trastuzumab, both administered via intravenous infusion. These drugs are combined with a physician’s choice of chemotherapy, including eribulin, vinorelbine, gemcitabine, or capecitabine, to treat HER2-positive metastatic breast cancer.

The study is designed as a randomized, open-label, multicenter trial with a parallel intervention model. There is no masking involved, and the primary purpose is treatment-focused, aiming to directly compare the two drug combinations.

Key dates for the study include its start on May 24, 2024, with the latest update provided on August 22, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence treatment protocols.

This study update could impact Jazz Pharmaceuticals’ stock performance positively if zanidatamab proves more effective, potentially enhancing investor sentiment. It also positions Jazz in a competitive stance within the oncology pharmaceutical market, particularly against companies focusing on HER2-positive breast cancer treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.